According to the Safety Announcement, the FDA is aware of a similar study conducted in France, which suggested an increased risk of bladder cancer for patients taking Actos® for over a year. In response to their study, France suspended the use of Actos® altogether and Germany has issued recommendations to physicians that no new patients be prescribed this drug.
